Ignite Creation Date:
2025-12-26 @ 10:34 AM
Ignite Modification Date:
2026-01-13 @ 12:50 PM
Study NCT ID:
NCT05495828
Status:
UNKNOWN
Last Update Posted:
2023-10-26
First Post:
2022-08-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors
Sponsor:
Peking University People's Hospital
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
intolerant to BTK inhibitors
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None